alexa Targeted Imaging For Personalized Medicine: New Age For Combination Cancer Treatments
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Nanotek & Expo
December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Ljubimova J Y, Patil R, Ding H, Portilla J, Gangalum P, Black K L and Holler E
ScientificTracks Abstracts: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439.S1.017
Abstract
Introduction: MRI enhancement in the brain may result from primary or recurrent brain tumor, radiation necrosis, metastasis from primary cancer (e.g., lung, breast), stroke, inflammation or infection. Biopsies of the brain are often technically impossible. The purpose was to establish the validity of a polymalic acid (PMLA)-based natural nanobiopolymer, PolycefinTM, for the differential tumor-type imaging of metastatic brain tumors. Methods: PolycefinTM contained covalently attached moieties for tumor-specific targeting (antibodies to EGFR or HER2/neu), tumor cell elimination (antisense oligos to EGFR or HER2), transcytosis across blood-brain tumor barrier (anti-transferrin receptor antibody), endosome disruption and drug release into the tumor cell cytoplasm (trileucine), and imaging (MRI tracer Gadolinium, Gd-DOTA). Nude mice had human EGFR+ (MDA-MB-468 breast cancer or A549 lung cancer) and HER2+ (MDA-MB-474 breast cancer) tumor cells stereotactically implanted, each in one brain hemisphere, and nanopolymer injected into the tail vein for imaging. Signals in healthy brain and tumor were quantified over time using 9.4-Tesla small animal MRI system (BioSpec). Results: After reaching a maximum in the first hour post injection, high signal values prevailed for 3 hours for Gd-DOTAPolycefin, but declined rapidly for clinical Gd. By differential MRI with anti-HER2 (Trastuzumab) or anti-EFGR (Cetuximab) antibody attached to PolycefinTM, it was possible to reliably differentiate HER2+ from EGFR+ metastatic brain tumors by noninvasive imaging. Conclusions: The PolycefinTM biopolymer appears to be highly suitable for non-invasive differential diagnosis of brain metastases from various tumors based on specific markers. This ?virtual biopsy? approach may assist in choosing the right treatment regimen.
Biography
Ljubimova J Y is a Professor and Director of Nanomedicine Research Center at the Department of Neurosurgery at Cedars-Sinai Medical Center. Her major interest is the differential cancer gene expression as a tool for finding novel/early markers of cancer development, and for working out new nanomedicine drugs against these tumor targets for treatment and/or imaging. One of the novel markers, the structural tumor vessel wall protein laminin-411, is currently in a clinical trial as a prognostic and diagnostic marker for human glial tumor progression. These discoveries led to the development of new technologies for drug delivery and engineering of the new class of anti-cancer nanomedicine drugs and imaging agents. Currently her research is supported by three NIH/NCI, private and industry grants. She is the author of over 70 peer review publications, reviews and book chapters as well as an inventor on 12 patents and patent applications.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords